Drug Profile
Biotin - MedDay Pharmaceuticals
Alternative Names: Coenzyme R; D-biotin; MD 1003; Qizenday; Vitamin HLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator MedDay Pharmaceuticals
- Class Anti-inflammatories; Carboxylic acids; Coenzymes; Imidazoles; Small molecules; Vitamins
- Mechanism of Action Biotin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Multiple sclerosis
- Discontinued Adrenoleucodystrophy; Adrenomyeloneuropathy; Amyotrophic lateral sclerosis; Charcot-Marie-Tooth disease; Chronic inflammatory demyelinating polyradiculoneuropathy; Encephalomyelitis
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Adrenoleucodystrophy in France
- 13 May 2020 MedDay Pharmaceuticals discontinues a phase I trial in Hepatic impairment in Hungary and France due to other Phase III trial failed to meet primary endpoint (NCT04252417)
- 20 Feb 2020 MedDay Pharmaceuticals initiates a phase I trial in healthy volunteers (NCT04168723)